Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006-10-20
Excessive toxicity when treating central tumors in a phase II study of stereotactic body radiation therapy for medically inoperable early-stage lung cancer.
ABSTRACT
PURPOSE
Surgical resection is standard therapy in stage I non-small-cell lung cancer (NSCLC); however, many patients are inoperable due to comorbid diseases. Building on a previously reported phase I trial, we carried out a prospective phase II trial using stereotactic body radiation therapy (SBRT) in this population.
PATIENTS AND METHODS
Eligible patients included clinically staged T1 or T2 (< or = 7 cm), N0, M0, biopsy-confirmed NSCLC. All patients had comorbid medical problems that precluded lobectomy. SBRT treatment dose was 60 to 66 Gy total in three fractions during 1 to 2 weeks.
RESULTS
All 70 patients enrolled completed therapy as planned and median follow-up was 17.5 months. The 3-month major response rate was 60%. Kaplan-Meier local control at 2 years was 95%. Altogether, 28 patients have died as a result of cancer (n = 5), treatment (n = 6), or comorbid illnesses (n = 17). Median overall survival was 32.6 months and 2-year overall survival was 54.7%. Grade 3 to 5 toxicity occurred in a total of 14 patients. Among patients experiencing toxicity, the median time to observation was 10.5 months. Patients treated for tumors in the peripheral lung had 2-year freedom from severe toxicity of 83% compared with only 54% for patients with central tumors.
CONCLUSION
High rates of local control are achieved with this SBRT regimen in medically inoperable patients with stage I NSCLC. Both local recurrence and toxicity occur late after this treatment. This regimen should not be used for patients with tumors near the central airways due to excessive toxicity.
Related Questions
Does tumor location play a role (central vs peripheral) in making the decision? The question stems from an oral presentation at ASTRO 2014 inves...
New comment by Radiation Oncologist at Anderson Regional Cancer Center ( January 2, 2020)
When doing the hypofractionated, SBRT-like regimens (8-15 fractions) do you typically do daily treatment?
Is there any concern about hemorrhage from treatment effect on tumor? Would SABR worsen the chance of fatal hemorrhage/hemoptysis and if so, would you...
New comment by Radiation Oncologist at University of Colorado School of Medicine ( June 5, 2015)
I agree with Dr Olivier's comments. Luckily, it is a rare event that radiation therapy makes hemoptysis worse. This should not be a reason to with hold radiation therapy. B...
The Indiana report and RTOG published a "danger zone". There was a catastrophic "case report" for 50 Gy in 5 fractions. Are there alternat...
New answer by Radiation Oncologist at OSF HealthCare Cancer Institute (October 13, 2018)
For the proton, I would consider 70 Gy in 10 fractions over 2 weeks. Bush et al reported their 12 years experience using passive scattered proton beam on 111 patients stage T...
What are the primary data that drove organ at risk and conformality dose constraints?
New answer by Radiation Oncologist at Cleveland Clinic (April 23, 2014)
This is a question that is frequently and appropriately asked by SBRT beginners and experienced practitioners. The history of SBRT in that regard replicates much of the histor...
Our dosimetrists rarely meet the RTOG constraint using a non-coplanar technique, especially for very small lesions. I haven't been able to find a corr...
New comment by Radiation Oncologist at University of Washington School of Medicine ( September 11, 2015)
I agree with both Ken and Cliff. In the RTOG 0236 trial, heterogeneity correction was not allowed and the original R50 parameters were set based on no heterogeneity correction...